FDA Quietly Consults Patients To Understand Six-Minute Walk Significance
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Meeting with Morquio A patient and caregivers appears to have helped to assuage FDA concerns about clinical relevance of the Vimizim trial’s primary endpoint – and illustrates FDA’s openness to patient input even during specific reviews of new product applications.